Delcath Systems, Inc.

How big is Delcath Systems, Inc.?

As of Jun 18, Delcath Systems, Inc. has a market capitalization of 509.51 million, with net sales of 53.85 million and a net profit of -14.21 million over the last four quarters. The company reported shareholder's funds of 68.75 million and total assets of 76.59 million as of Dec 24.

Market Cap: As of Jun 18, Delcath Systems, Inc. has a market capitalization of 509.51 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Delcath Systems, Inc. reported net sales of 53.85 million and a net profit of -14.21 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 68.75 million and total assets of 76.59 million.

What does Delcath Systems, Inc. do?

Delcath Systems, Inc. is a late-stage clinical development company focused on liver cancer treatments, with recent net sales of $20 million and a market cap of $509.51 million. The company is currently not profitable, with a net profit of $1 million reported for March 2025.

Overview:<BR>Delcath Systems, Inc. is a late-stage clinical development company in the Pharmaceuticals & Biotechnology industry, focusing on cancers of the liver.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 20 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 1 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 509.51 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.73<BR>- Return on Equity: -0.93%<BR>- Price to Book: 6.35<BR><BR>Contact Details:<BR>- Address: 1633 Broadway Ste 22C, NEW YORK NY: 10019-6708<BR>- Tel: 1 212 4892100<BR>- Fax: 1 212 4892102<BR>- Website: http://delcath.com/

Should I buy, sell or hold Delcath Systems, Inc.?

Who are in the management team of Delcath Systems, Inc.?

As of March 2022, the management team of Delcath Systems, Inc. includes Dr. Roger Stoll (Non-Executive Independent Chairman), Mr. Gerard Michel (CEO and Director), and several Independent Directors: Dr. Gilad Aharon, Ms. Elizabeth Czerepak, Mr. Steven Salamon, and Mr. John Sylvester. This team provides executive leadership and governance for the company.

As of March 2022, the management team of Delcath Systems, Inc. includes the following individuals:<BR><BR>- Dr. Roger Stoll, who serves as the Non-Executive Independent Chairman of the Board.<BR>- Mr. Gerard Michel, who is the Chief Executive Officer and a Director.<BR>- Dr. Gilad Aharon, who is an Independent Director.<BR>- Ms. Elizabeth Czerepak, who is also an Independent Director.<BR>- Mr. Steven Salamon, serving as an Independent Director.<BR>- Mr. John Sylvester, who is another Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is Delcath Systems, Inc. technically bullish or bearish?

As of August 12, 2025, the trend has shifted to mildly bearish due to bearish weekly MACD and KST indicators, despite mixed signals across timeframes and a bullish monthly view.

As of 12 August 2025, the technical trend has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and KST indicators, both of which are bearish. The daily moving averages also reflect a mildly bearish sentiment. The Bollinger Bands indicate a mildly bearish trend on the weekly timeframe, while the monthly view shows a bullish signal. Overall, the mixed signals across different timeframes suggest caution. There is no available multi-period return data to compare the stock's performance against the S&P 500.

Is Delcath Systems, Inc. overvalued or undervalued?

As of October 17, 2025, Delcath Systems, Inc. is considered overvalued with a valuation grade of expensive, reflected in its high valuation ratios compared to peers and a lack of positive returns relative to the S&P 500.

As of 17 October 2025, the valuation grade for Delcath Systems, Inc. has moved from fair to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its significant valuation ratios, including a Price to Book Value of 7.11, an EV to Capital Employed of 23.86, and an EV to Sales of 9.50. In comparison to its peers, Delcath's P/E ratio of 68.06 stands in stark contrast to iCAD, Inc. at -19.65 and Eargo, Inc. at -0.61, highlighting its relative overvaluation within the industry.<BR><BR>While specific return data is not available, the absence of positive returns in the context of the S&P 500 further reinforces the notion that Delcath Systems, Inc. is not only overvalued but may also be struggling to deliver shareholder value in the current market environment.